Abstract
Lithium treatment history goes far back before it was thoroughly described in the literature which is now available to us. However, disorders that were initially treated with lithium salts were completely unrelated to psychiatry. The article “Lithium salts in the treatment of psychotic excitement” from 1949 written by John Cade is considered to be the introduction of lithium to modern psychiatric therapy and the beginning of modern clinical psychopharmacology.
In the present treatment guidelines for bipolar disorders lithium is recommended as a first-line maintenance therapy. What is worth mentioning is that the number of indications, including major depressive disorder, for instance, is growing. In addition, numerous meta-analyses focused on antisuicidal effect of lithium therapy were also performed.
On the basis of the most recent literature available in this paper we presented indications for the preventive use of lithium for such disorders as mania, bipolar disorder as well as the occurrence of depressive episodes in major depressive disorder. It is worth pointing out that some studies indicate lithium to be the only medicine proved to be effective for mood stabilization. Interactions between lithium and other medicines were described in detail. In this paper we also described and discussed possible side effects of lithium therapy, including renal failure, hypothyroidism, hyperparathyroidism, weight gain and teratogenicity.
Keywords: Bipolar disorder, depression, lithium, mania, meta-analysis, suicide.
Current Psychopharmacology
Title:Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Volume: 3
Author(s): Joanna Iskra-Trifunovic, Mateusz Szymczak, Andrzej Jasiewicz, Anna Grzywacz and Jerzy Samochowiec
Affiliation:
Keywords: Bipolar disorder, depression, lithium, mania, meta-analysis, suicide.
Abstract: Lithium treatment history goes far back before it was thoroughly described in the literature which is now available to us. However, disorders that were initially treated with lithium salts were completely unrelated to psychiatry. The article “Lithium salts in the treatment of psychotic excitement” from 1949 written by John Cade is considered to be the introduction of lithium to modern psychiatric therapy and the beginning of modern clinical psychopharmacology.
In the present treatment guidelines for bipolar disorders lithium is recommended as a first-line maintenance therapy. What is worth mentioning is that the number of indications, including major depressive disorder, for instance, is growing. In addition, numerous meta-analyses focused on antisuicidal effect of lithium therapy were also performed.
On the basis of the most recent literature available in this paper we presented indications for the preventive use of lithium for such disorders as mania, bipolar disorder as well as the occurrence of depressive episodes in major depressive disorder. It is worth pointing out that some studies indicate lithium to be the only medicine proved to be effective for mood stabilization. Interactions between lithium and other medicines were described in detail. In this paper we also described and discussed possible side effects of lithium therapy, including renal failure, hypothyroidism, hyperparathyroidism, weight gain and teratogenicity.
Export Options
About this article
Cite this article as:
Iskra-Trifunovic Joanna, Szymczak Mateusz, Jasiewicz Andrzej, Grzywacz Anna and Samochowiec Jerzy, Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders, Current Psychopharmacology 2014; 3 (1) . https://dx.doi.org/10.2174/2211556003666140319231533
DOI https://dx.doi.org/10.2174/2211556003666140319231533 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Triazino-caffeine Derivatives by Intramolecular Cyclization: Synthesis, Characterization and Antimicrobial Studies
Letters in Organic Chemistry Biological Evaluation of Imidazobenzoxazines, Imidazobenzoxazin-5-ones and Imidazobenzoxazin-5-thiones as Sodium Channel Blockers
Letters in Drug Design & Discovery PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Synaptic Plasticity, Metaplasticity and Depression
Current Neuropharmacology Zinc-Permeable Ion Channels: Effects on Intracellular Zinc Dynamics and Potential Physiological/Pathophysiological Significance
Current Medicinal Chemistry Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings
Current Drug Discovery Technologies Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacological Effects and Chemical Constituents of Bupleurum
Mini-Reviews in Medicinal Chemistry Beyond the Synapse and Hebb's Rule: Is the Rest of the Neuron More Important for Psychiatric Disorders?
Current Psychiatry Reviews Valproic Acid Metabolism and its Consequences on Sexual Functions
Current Drug Metabolism Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Cofactors and Metabolites as Protein Folding Helpers in Metabolic Diseases
Current Topics in Medicinal Chemistry Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Combined Virtual Screening Strategies
Current Computer-Aided Drug Design Editorial [Hot topic: Adenosine Receptor Ligands: Where Are We, and Where Are We Going? (Guest Editors: Tiziano Tuccinardi and Adriano Martinelli)]
Current Topics in Medicinal Chemistry Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Voltage-Gated Sodium Channels in Neurological Disorders
CNS & Neurological Disorders - Drug Targets GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets Mitochondrial Disorders in Adults
Current Molecular Medicine Delineating Somatostatins Neuronal Actions
Current Drug Targets - CNS & Neurological Disorders